Investors and Media
Idera Pharmaceuticals is a clinical-stage biopharmaceutical company developing tilsotolimod, a Toll-like receptor (TLR) 9 agonist for the treatment of certain cancers. Tilsotolimod is focused on priming the immune system to play a more powerful role in fighting cancer, ultimately increasing the number of people who can benefit from immunotherapy. Idera is also focused on the acquisition, development and ultimate commercialization of drug candidates for both oncology and rare disease indications characterized by small, well-defined patient populations with serious unmet needs..
Jan 11, 2021
Dec 15, 2020
Nov 17, 2020
Data Provided by Refinitiv. Minimum 15 minutes delayed.